Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2020

Open Access 01-12-2020 | Pancreatic Cancer | Research

The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection

Authors: Laura van Wijk, Guus W. de Klein, Matthijs A. Kanters, Gijs A. Patijn, Joost M. Klaase

Published in: European Journal of Medical Research | Issue 1/2020

Login to get access

Abstract

Background

Emerging evidence indicates that an elevated C-reactive protein-to-albumin ratio (CAR) may be associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Further evidence showing that this ratio has significant prognostic value could contribute to current prediction models and clinical decision-making.

Methods

Data were analysed of consecutive patients who underwent curative pancreatic resection between 2013 and 2018 and were histologically diagnosed with PDAC. We investigated the relation between the ultimate preoperative CAR and overall survival.

Results

A total of 163 patients were analysed. Median overall survival was 18 months (IQR 9–36). Multivariate analysis demonstrated that a higher CAR (HR 1.745, P = 0.004), a higher age (HR 1.062, P < 0.001), male sex (HR 1.977, P = 0.001), poor differentiation grade (HR 2.812, P < 0.001), and positive para-aortic lymph node(s) (HR 4.489, P < 0.001) were associated with a lower overall survival. Furthermore, a CAR ≥ 0.2 was associated with decreased overall survival (16 vs. 26 months, P = 0.003).

Conclusion

We demonstrated that an ultimate preoperative elevated CAR is an independent indicator of decreased overall survival after resection for PDAC. The preoperative CAR may be of additional value to the current prediction models.
Literature
1.
2.
Wu M, Guo J, Guo L, Zuo Q. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol. 2016;37(9):12525–33.PubMedCrossRef
3.
Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y, et al. The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg. 2016;40(9):2254–60.PubMedCrossRef
4.
Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery. 2015;158(2):360–5.PubMedCrossRef
5.
Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, et al. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: a Retrospective Multicenter Cohort Study. Ann Surg. 2019;270(1):139–46.PubMedCrossRef
6.
Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–100.PubMedCrossRef
7.
Chen J, Gu Z, Wu M, Yang Y, Zhang J, Ou J, et al. C-reactive protein can upregulate VEGF expression to promote ADSC-induced angiogenesis by activating HIF-1alpha via CD64/PI3k/Akt and MAPK/ERK signaling pathways. Stem Cell Res Ther. 2016;7(1):114.PubMedPubMedCentralCrossRef
8.
Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, et al. Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget. 2016;7(46):75013–22.PubMedPubMedCentralCrossRef
9.
Wong VK, Malik HZ, Hamady ZZ, Al-Mukhtar A, Gomez D, Prasad KR, et al. C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer. 2007;96(2):222–5.PubMedPubMedCentralCrossRef
10.
Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Okuyama H, et al. C-reactive protein level is an indicator of the aggressiveness of advanced pancreatic cancer. Pancreas. 2016;45(1):110–6.PubMedCrossRef
11.
Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol. 2009;35(6):605–10.PubMedCrossRef
12.
Chiang JM, Chang CJ, Jiang SF, Yeh CY, You JF, Hsieh PS, et al. Pre-operative serum albumin level substantially predicts post-operative morbidity and mortality among patients with colorectal cancer who undergo elective colectomy. Eur J Cancer Care. 2017. https://​doi.​org/​10.​1111/​ecc.​12403Epub 2015 Nov 3.CrossRef
13.
Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015;7(12):370–7.PubMedPubMedCentralCrossRef
14.
Abe T, Nakata K, Kibe S, Mori Y, Miyasaka Y, Ohuchida K, et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(13):3996–4003.PubMedCrossRef
15.
Fu YJ, Li KZ, Bai JH, Liang ZQ. C-reactive protein/albumin ratio is a prognostic indicator in Asians with pancreatic cancers: a meta-analysis. Medicine. 2019 November 01;98(48):e18219.PubMedPubMedCentralCrossRef
16.
Zang Y, Fan Y, Gao Z. Pretreatment C-reactive protein/albumin ratio for predicting overall survival in pancreatic cancer: a meta-analysis. Medicine. 2020;99(23):e20595.PubMedPubMedCentralCrossRef
17.
Strijker M, Chen JW, Mungroop TH, Jamieson NB, van Eijck CH, Steyerberg EW, et al. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Br J Surg. 2019;106(4):342–54.PubMedCrossRef
18.
Proctor MJ, Morrison DS, Talwar D, Balmer SM, O’Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–34.PubMedPubMedCentralCrossRef
19.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMedCrossRef
20.
La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19(9):2917–23.PubMedCrossRef
21.
Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011;18(8):2318–28.PubMedCrossRef
22.
Numata K, Morinaga S, Katayama Y, Sawazaki S, Numata M, Godai T, et al. Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine. Anticancer Res. 2016;36(5):2467–74.PubMed
23.
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–72.PubMedCrossRef
24.
McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210–3.PubMedCrossRef
25.
Barber MD, Ross JA, Fearon KC. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35(2):106–10.PubMedCrossRef
26.
Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet. 1985;1(8432):781–4.PubMedCrossRef
27.
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012;33(3):209–90.PubMedCrossRef
28.
Wahi MM, Shah N, Schrock CE, Rosemurgy AS, Goldin SB. Reproductive factors and risk of pancreatic cancer in women: a review of the literature. Ann Epidemiol. 2009;19(2):103–11.PubMedCrossRef
29.
(29) van der Geest, L G, Besselink MG, van Gestel YR, Busch OR, de Hingh IH, de Jong KP, et al. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol 2016;55(3):278-285.
30.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMedCrossRef
31.
32.
van Erning FN, Mackay TM, van der Geest LGM, Groot Koerkamp B, van Laarhoven HWM, Bonsing BA, et al. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol. 2018;57(12):1655–62.PubMedCrossRef
33.
Sheng W, Dong M, Wang G, Shi X, Gao W, Wang K, et al. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study. BMC Cancer 2019 October 22;19(1):981-z.
34.
Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016 March 15;4:14-z. eCollection 2016.
35.
Wang Y, Xiao X, Wang T, Li L, Zhu Y, Xu H, et al. A survival model in locally advanced and metastatic pancreatic ductal adenocarcinoma. J Cancer. 2018;9(7):1301–7.PubMedPubMedCentralCrossRef
36.
La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, et al. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver. 2014;8(1):102–8.PubMedCrossRef
37.
Kaissis G, Ziegelmayer S, Lohofer F, Algul H, Eiber M, Weichert W, et al. A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. Eur Radiol Exp. 2019;3(1):41.PubMedPubMedCentralCrossRef
38.
Eilaghi A, Baig S, Zhang Y, Zhang J, Karanicolas P, Gallinger S, et al. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma–a quantitative analysis. BMC Med Imaging. 2017;17(1):38.PubMedPubMedCentralCrossRef
Metadata
Title
The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection
Authors
Laura van Wijk
Guus W. de Klein
Matthijs A. Kanters
Gijs A. Patijn
Joost M. Klaase
Publication date
01-12-2020
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2020
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-020-00444-z

Other articles of this Issue 1/2020

European Journal of Medical Research 1/2020 Go to the issue

Review

Face masks: benefits and risks during the COVID-19 crisis

Correction

Correction to: The role of passive immunization in the age of SARS-CoV-2: an update

Research

Comparison of three fixation methods for orotracheal intubation in 95 adults

Research

A preclinical animal model for evaluating the sealing capacity of covered stent grafts in acute vessel perforation

Research

The role of phagocytic leukocytes following flexible ureterenoscopy, for the treatment of kidney stones: an observational, clinical pilots-study

Research

Prevalence and distribution of resistance and enterotoxins/enterotoxin-like genes in different clinical isolates of coagulase-negative Staphylococcus